I sat down with NImmune CEO Josep Bassaganya-Riera to talk about omilancor, their gut-restricted oral IBD drug now in Phase 3 clinical trials. We cover LANCL2 biology, their biomarker aimed at boosting response rates, and the TITAN-X platform that helps guide real development decisions. A really interesting look at how you build an oral immunology company in 2025.Follow Biotech Blueprint for free at https://www.biotechblueprint.com/NImmune Biopharma: https://nimmunebio.com/Josep's LinkedIn profile: https://www.linkedin.com/in/josep-bassaganya-riera/ Connect with me on LinkedIn: https://www.linkedin.com/in/katerina-roznik/